Wall Street brokerages expect Davita Inc (NYSE:DVA) to announce earnings per share (EPS) of $1.00 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Davita’s earnings, with the lowest EPS estimate coming in at $0.93 and the highest estimate coming in at $1.16. Davita reported earnings per share of $1.05 during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.8%. The company is scheduled to issue its next quarterly earnings results on Thursday, May 2nd.

On average, analysts expect that Davita will report full year earnings of $4.42 per share for the current year, with EPS estimates ranging from $3.61 to $4.95. For the next financial year, analysts forecast that the company will post earnings of $5.40 per share, with EPS estimates ranging from $4.59 to $6.88. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Davita.

Davita (NYSE:DVA) last released its quarterly earnings data on Wednesday, February 13th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.01. Davita had a net margin of 1.40% and a return on equity of 13.75%. The firm had revenue of $2.82 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis.

Several research firms recently commented on DVA. Raymond James downgraded shares of Davita from a “strong-buy” rating to a “market perform” rating in a research note on Thursday, November 8th. TheStreet downgraded shares of Davita from a “b-” rating to a “c+” rating in a research note on Thursday, November 8th. Royal Bank of Canada upped their price target on shares of Davita from $70.00 to $78.00 and gave the company a “sector perform” rating in a research note on Thursday, November 8th. Zacks Investment Research downgraded shares of Davita from a “hold” rating to a “sell” rating in a research note on Tuesday, November 13th. Finally, UBS Group began coverage on shares of Davita in a research note on Thursday, November 15th. They issued a “sell” rating and a $64.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $66.92.

Several hedge funds have recently added to or reduced their stakes in DVA. BlackRock Inc. grew its stake in shares of Davita by 34.0% in the fourth quarter. BlackRock Inc. now owns 12,931,031 shares of the company’s stock valued at $665,428,000 after acquiring an additional 3,280,413 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Davita by 4,995.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,880,451 shares of the company’s stock worth $37,000 after purchasing an additional 1,843,544 shares during the period. Pendal Group Ltd bought a new stake in Davita during the third quarter worth about $961,000. DPM Capital LLC bought a new stake in Davita during the fourth quarter worth about $36,220,000. Finally, Caption Management LLC lifted its position in Davita by 100.7% during the fourth quarter. Caption Management LLC now owns 3,200 shares of the company’s stock worth $164,000 after purchasing an additional 488,800 shares during the period. Institutional investors and hedge funds own 85.99% of the company’s stock.

DVA stock opened at $59.10 on Thursday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 1.82 and a current ratio of 1.84. Davita has a 52 week low of $48.25 and a 52 week high of $79.11. The stock has a market capitalization of $9.81 billion, a P/E ratio of 16.55, a price-to-earnings-growth ratio of 0.59 and a beta of 1.31.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Recommended Story: No Load Funds

Get a free copy of the Zacks research report on Davita (DVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.